NCT02414269 2025-10-08Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen MesothelinMemorial Sloan Kettering Cancer CenterPhase 1/2 Active not recruiting113 enrolled